WEBULL

Genky DrugStores (TSE:9267) Stock Rallies As Thin Margins Meet Premium P E

Simply Wall St · 2d ago

Genky DrugStores stock has been on a tear, with double digit gains over the past month, yet today’s close near ¥4,170 suggests investors are still willing to pay up for the story. The hook in this earnings print is not a one off EPS surprise. It is the tension between solid profit generation and a valuation that already bakes in a lot of optimism.

Net profit margin sits at 3.6% and the trailing P/E around 16.2x remains richer than many consumer retail peers. The market is treating Genky DrugStores as a premium compounder, and today’s reaction tests how comfortable investors really are with that premium.

Is Genky DrugStores trading at a justifiable premium for its 3.6% net margin and TTM EPS of ¥258.51, or are investors stretching too far on story over fundamentals? Compare the current market price with our valuation analysis for Genky DrugStores

FY 2026 Earnings Summary

  • Revenue (FY 2026 TTM vs. FY 2025 TTM): ¥220,638 million vs. ¥200,786 million (higher on a trailing twelve month basis)
  • Net Income (Excl. Extra Items, FY 2026 TTM vs. FY 2025 TTM): ¥7,875 million vs. ¥7,066 million (higher on a trailing twelve month basis)
  • Basic EPS (Earnings Per Share, FY 2026 TTM vs. FY 2025 TTM): ¥258.51 vs. ¥232.49 (higher on a trailing twelve month basis)
  • Net Profit Margin (FY 2026 vs. FY 2025): 3.6% vs. 3.5% (slight improvement in profitability)

Prefer clear charts instead of scrolling through more text and raw figures? Get a full visual view of Genky DrugStores, including how the market is pricing its earnings power, in our company report for Genky DrugStores.

TSE:9267 Trailing 12-Month Earnings & Revenue History as at Jul 2026
TSE:9267 Trailing 12-Month Earnings & Revenue History as at Jul 2026

Genky DrugStores earnings support a steady bull story

For investors leaning positive on Genky DrugStores as a steady everyday essentials play, the latest numbers offer some support. Revenue on a trailing basis is at ¥220,638 million, with net income at ¥7,875 million and basic EPS at ¥258.51. Profitability is holding at a 3.6% net margin. That small step up from 3.5% signals the model is at least holding its ground in a competitive food and drug market, which lines up with the defensive, repeat purchase narrative.

Genky DrugStores results leave room for caution

The bear story around margin pressure in Japanese drugstores is not erased by this set of results. Net profit margin is only 3.6%, so even a small slip in pricing or costs could matter. The improvement from 3.5% is incremental rather than transformational. That keeps questions alive about how much room Genky DrugStores really has to absorb competition or higher expenses without putting earnings under strain.

After such slim margins, even modest execution errors or higher financing costs could matter. Review whether Genky DrugStores faces deeper structural threats in our risk analysis for Genky DrugStores which shows 1 important warning sign.

Stay Ahead With Simply Wall St

If Genky DrugStores looks interesting after its recent double digit share price move and 3.6% net margin, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and wait for a setup that fits your plan. When you decide to take a position, use the Portfolio Command Center to cut through market noise and focus on the updates that really affect your holdings. For longer term thinking, tap into the Community to see how other investors are interpreting the same numbers and risks. This way you spot potential catalysts and red flags early and keep yourself one step ahead of the market.

Seeking Alternatives Beyond Genky DrugStores?

Fresh stock ideas can start moving quickly once momentum builds. The best entry points often pass quietly under the radar for now, so consider acting promptly if an idea fits your strategy.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.